Anti-Fibrinolytic Drugs - Russia

Russia

In Russia, the revenue in the Anti-Fibrinolytic Drugs market is predicted to reach US$111.10m in 2024.
It is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 4.05%, leading to a market volume of US$135.50m by 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to US$9,858.00m in 2024.
In Russia, the demand for anti-fibrinolytic drugs is increasing due to the rising prevalence of cardiovascular diseases and the aging population.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Fibrinolytic Drugs market in Russia has witnessed significant growth in recent years.

Customer preferences: Patients in Russia suffering from bleeding disorders such as hemophilia and von Willebrand disease prefer anti-fibrinolytic drugs due to their ability to prevent excessive bleeding. Additionally, these drugs are also used in surgical procedures to reduce blood loss.

Trends in the market: The market for anti-fibrinolytic drugs in Russia has been driven by the increasing incidence of bleeding disorders, especially among children. There has also been a rise in the number of surgeries being performed in the country, leading to a higher demand for these drugs. Furthermore, the availability of newer and more effective drugs has also contributed to the growth of the market.

Local special circumstances: The Russian government has been investing heavily in the healthcare sector, which has led to the development of better healthcare infrastructure and increased access to medical facilities. This has played a significant role in the growth of the anti-fibrinolytic drugs market in the country. Additionally, the government has also implemented various initiatives to raise awareness about bleeding disorders and the importance of early diagnosis and treatment.

Underlying macroeconomic factors: The overall growth of the healthcare sector in Russia has been driven by the country's improving economic conditions. The increase in disposable income has led to a higher demand for quality healthcare services, including the use of anti-fibrinolytic drugs. Furthermore, the government's focus on healthcare has also led to an increase in healthcare spending, which has benefited the anti-fibrinolytic drugs market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.